Form 4: Macrogenics CFO Vests, Sells Shares for Tax

Macrogenics' SVP and CFO, James Karrels, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• James Karrels, SVP and CFO of Macrogenics Inc. (MGNX), reported transactions involving the company's common stock on February 7 and 8, 2026.
• On February 7, 2026, Karrels acquired 6,334 shares of common stock through the vesting of restricted stock units (RSUs) and simultaneously disposed of 2,446 shares at a price of $1.81 per share to cover tax liabilities.
• On February 8, 2026, he acquired an additional 9,999 shares of common stock from RSU vesting and disposed of 3,860 shares at $1.81 per share for tax purposes.
• The RSU acquisitions relate to grants made on February 7, 2025 (19,000 units, vesting in three equal installments) and February 8, 2024 (30,000 units, vesting in three equal installments).
• Following these transactions, Karrels beneficially owns 196,828 shares of common stock directly, jointly with his wife.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal. While there are dispositions, they are explicitly for tax purposes following RSU vesting, and the executive's overall beneficial ownership has increased, indicating continued alignment with shareholder interests.

Positives

• The vesting of restricted stock units indicates continued compensation and retention of a key executive.
• The executive acquired a total of 16,333 shares through RSU vesting over the two days.
• The final beneficial ownership of 196,828 shares represents a net increase in the executive's holdings over the reported period, demonstrating continued alignment with shareholder interests.

Negatives

• The disposition of 6,306 shares (2,446 + 3,860) for tax purposes reduces the executive's direct holdings, although this is a standard practice.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to RSU vesting and tax-related sales, are common occurrences in the biotechnology and pharmaceutical sectors. These transactions reflect standard executive compensation practices and do not necessarily indicate a change in management's outlook on the company's prospects, especially when a significant portion of vested shares are retained.

Stakeholder Impact

• Shareholders: The increase in the CFO's beneficial ownership, even after tax-related sales, generally signals continued confidence in the company's future, which can be viewed positively by shareholders.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation (RSU vesting and tax-related sales). While the CFO's beneficial ownership slightly increased, these are not discretionary purchases or sales that would typically warrant a change in investment recommendation. The transactions are expected and do not provide new fundamental information about the company's operational performance or strategic direction.

Keywords

Macrogenics, MGNX, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Executive Compensation, James Karrels, SVP and CFO, Stock Transaction